Real-World Use of Glucagon-Like Peptide 1 Receptor Agonists in Patients with MASLD: A Cross-Sectional Analysis from TARGET-NASH.

Challenge

Despite regulatory and commercial interest in GLP-1 RAs for MASH, real-world data on the actual breadth of their use in MASLD—who receives them, for how long, why they are discontinued, and whether their use differs by disease phenotype—were lacking before pivotal trial results were available.

Solution

A cross-sectional analysis of the TARGET-NASH cohort characterized GLP-1 RA prescribing patterns by phenotype (MASL, MASH, cirrhosis), patient demographics, duration of use, and reasons for treatment disruption, providing a contemporaneous real-world baseline ahead of regulatory approval decisions.

Impact

Establishing pre-approval real-world prescribing patterns for GLP-1 RAs in MASLD creates a natural history baseline for post-authorization effectiveness studies and informs launch strategy for sponsors by characterizing the existing treatment landscape before label-endorsed use begins.